Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia | Current Treatment: Physician Insights | US | 2016

Non-Hodgkin’s lymphoma represents a segment of heterogeneous disease with multiple indolent and aggressive subtypes. The antineoplastic treatment rate in B-cell NHL patients is typically high because patients will require drug-treatment either at the time of diagnosis or after watchful waiting. The choice of treatment for NHL depends on the NHL subpopulation, line of therapy, and various prognostic factors that predict the outcome. The commercial opportunity for drug developers is significant, however the rapidly changing treatment landscape across lucrative market segments and the advent of new targeted therapies provides challenges as well as opportunities. This analysis provides insight on current use of approved therapies for NHL/CLL in the US and on oncologists’ perception of these therapies.

launch Related Market Assessment Reports